De Novo requests under 21 CFR 860.220 must include device details, labeling, testing, risk mitigations, and proposed controls. FDA’s eSTAR template streamlines submission, reduces errors, and links risks to objective evidence.
The content of a De Novo submission is defined in 21 CFR 860.220 and includes the following key elements:
Justifying any omissions in your submission is required to meet FDA expectations.

Format matters. FDA’s Electronic Submission Template And Resource (eSTAR) guidance for De Novo (updated August 2024) details how to structure and electronically transmit your request to CDRH/CBER. Using eSTAR reduces formatting errors and speeds intake, improving your submission’s efficiency.

Tie each identified risk to a mitigation strategy and provide supporting evidence. If proposing special controls, ensure they are:
Reference applicable consensus standards where relevant to strengthen your submission.

